Danifexor

N/A

Report date: 2025/05/23 14:39:04
NME

Base Information

Drug NameDanifexor
Drug Alias NameASC-42
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBile acid receptor FXR agonists
TargetsBile acid receptor FXR
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, SclerosingCholangitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAscletis Biological Technology (Hangzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAscletis Pharma IncGannex Pharma Co LtdAscletis Biological Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, SclerosingCholangitis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A